{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:57:07Z","timestamp":1771664227810,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T00:00:00Z","timestamp":1557446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00105-019-4414-8","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T12:49:45Z","timestamp":1557492585000},"page":"641-644","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["M\u00f6gliche Wirkung einer Interleukin-17-Blockade beim Pemphigus foliaceus und neutrophilen Erkrankungen","Possible effect of interleukin-17 blockade in pemphigus foliaceus and neutrophilic diseases"],"prefix":"10.1007","volume":"70","author":[{"given":"Johannes","family":"Kohlmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Christoph","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Treudler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,10]]},"reference":[{"key":"4414_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jdermsci.2008.09.008","volume":"53","author":"M Arakawa","year":"2009","unstructured":"Arakawa M, Dainichi T, Yasumoto S et\u00a0al (2009) Lesional Th17 cells in pemphigus vulgaris and pemphigus foliaceus. J\u00a0Dermatol Sci 53:228\u2013231","journal-title":"J Dermatol Sci"},{"key":"4414_CR2","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/ddg.12619","volume":"14","author":"S Claus","year":"2016","unstructured":"Claus S, Ziemer M, Simon JC et\u00a0al (2016) Coincidence of annular pustular psoriasis, pemphigus foliaceus, and leukocytoclastic vasculitis associated with chronic cholecystitis. J\u00a0Dtsch Dermatol Ges 14:830\u2013831","journal-title":"J Dtsch Dermatol Ges"},{"key":"4414_CR3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/1346-8138.13306","volume":"43","author":"S Imafuku","year":"2016","unstructured":"Imafuku S, Honma M, Okubo Y et al (2016) Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study. J\u00a0Dermatol 43:1011\u20131017","journal-title":"J Dermatol"},{"key":"4414_CR4","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.4049\/jimmunol.1600138","volume":"197","author":"R Liu","year":"2016","unstructured":"Liu R, Lauridsen HM, Amezquita RA et al (2016) IL-17 promotes neutrophil-mediated immunity by activating microvascular pericytes and not endothelium. J\u00a0Immunol 197:2400\u20132408","journal-title":"J Immunol"},{"key":"4414_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1046\/j.1365-2133.2001.04297.x","volume":"145","author":"K Matsuo","year":"2001","unstructured":"Matsuo K, Komai A, Ishii K et\u00a0al (2001) Pemphigus foliaceus with prominent neutrophilic pustules. Br J Dermatol 145:132\u2013136","journal-title":"Br J Dermatol"},{"key":"4414_CR6","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/cup.12793","volume":"43","author":"S Mendez-Flores","year":"2016","unstructured":"Mendez-Flores S, Avalos-Diaz E, Dominguez-Cherit J et al (2016) Pemphigus foliaceus with circinated plaques and neutrophil pustules. J\u00a0Cutan Pathol 43:1062\u20131066","journal-title":"J Cutan Pathol"},{"key":"4414_CR7","first-page":"174","volume":"13","author":"H Mortazavi","year":"2014","unstructured":"Mortazavi H, Esmaili N, Khezri S et\u00a0al (2014) The effect of conventional immunosuppressive therapy on cytokine serum levels in pemphigus vulgaris patients. Iran J Allergy Asthma Immunol 13:174\u2013183","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"4414_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2249.2009.03944.x","volume":"157","author":"A Nalbandian","year":"2009","unstructured":"Nalbandian A, Crispin JC, Tsokos GC (2009) Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 157:209\u2013215","journal-title":"Clin Exp Immunol"},{"key":"4414_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1046\/j.1365-2249.2000.01104.x","volume":"119","author":"EA O\u2019toole","year":"2000","unstructured":"O\u2019toole EA, Mak LL, Guitart J et al (2000) Induction of keratinocyte IL-8 expression and secretion by IgG autoantibodies as a\u00a0novel mechanism of epidermal neutrophil recruitment in a\u00a0pemphigus variant. Clin Exp Immunol 119:217\u2013224","journal-title":"Clin Exp Immunol"},{"key":"4414_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.5114\/ada.2016.61599","volume":"33","author":"A Wasilewska","year":"2016","unstructured":"Wasilewska A, Winiarska M, Olszewska M et al (2016) Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases. Postepy Dermatol Alergol 33:247\u2013252","journal-title":"Postepy Dermatol Alergol"},{"key":"4414_CR11","doi-asserted-by":"publisher","first-page":"463928","DOI":"10.1155\/2014\/463928","volume":"2014","author":"J Xue","year":"2014","unstructured":"Xue J, Su W, Chen Z et al (2014) Overexpression of interleukin-23 and interleukin-17 in the lesion of pemphigus vulgaris: a\u00a0preliminary study. Mediators Inflamm 2014:463928","journal-title":"Mediators Inflamm."},{"key":"4414_CR12","doi-asserted-by":"publisher","first-page":"8980534","DOI":"10.1155\/2017\/8980534","volume":"2017","author":"A Zebrowska","year":"2017","unstructured":"Zebrowska A, Wozniacka A, Juczynska K et\u00a0al (2017) Correlation between IL36alpha and IL17 and activity of the disease in selected autoimmune blistering diseases. Mediators Inflamm 2017:8980534","journal-title":"Mediators Inflamm."}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-019-4414-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-019-4414-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-019-4414-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:09:33Z","timestamp":1588964973000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-019-4414-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,10]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["4414"],"URL":"https:\/\/doi.org\/10.1007\/s00105-019-4414-8","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,10]]},"assertion":[{"value":"10 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Kohlmann erhielt finanzielle Unterst\u00fctzung zur Kongressteilnahme von Ipsen, AbbvVie und Lilly. J.C.\u00a0Simon erhielt Vertragshonorare von Novartis Pharma und f\u00fchrte klinische Studien f\u00fcr Novartis Pharma durch. M.\u00a0Kunz erhielt Honorare als \u00e4rztlicher Beirat von Novartis Pharma und Leo Pharma. R.\u00a0Treudler erhielt Vertragshonorare von Novartis Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}